ReviewEuropean cardiology2025
Development of Small-molecule SERCA2a Stimulators: A Novel Class of Ino-lusitropic Agents.
Review in European cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ca2+ signalling in cardiac muscle: the importance of balances.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Review
- Review
- Electrophysiological and biophysical perspectives on the clitoral corpus cavernosum and its role in female sexual arousal disorder.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term use of modulators of myocardial function has been scaled down because of the partially detrimental effects of currently available agents. Nonetheless, inotropy and lusitropy remain unmet needs in the treatment of chronic heart failure (HF). This underlies the interest in SERCA2a stimulation, a novel approach. This short review describes the identification of SERCA2a stimulating activity in istaroxime, an inotropic compound characterised by its minimal proarrhythmic effects despite its multiple targets, and the development of its derivatives into a novel class of ino-lusitropic agents. The benefits achieved with istaroxime derivatives (versus istaroxime) consist of their selectivity for SERCA2a stimulation and pharmacokinetics suitable for chronic oral administration. Considering the role of SERCA2a depression in HF and the accompanying electrical instability, selective restoration of SERCA2a function provides an appealing approach to HF therapy. Beneficial effects of SERCA2a stimulation by istaroxime have also been recently described in non-cardiac tissues, thus suggesting even broader and unexpected indications for this new class of agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.